GlaxoSmithKline (GSK) has reached a $2.2 billion settlement to resolve litigation from approximately 80,000 claimants in the U.S. who alleged that its heartburn drug Zantac caused cancer. The settlement covers 93% of pending cases and does not involve an admission of liability by GSK.